Clinical trials: Vaccination; Infection
COVID-19
Correlation Study of Isotype Switching and Neutralizing Capacity to the COVID-19 Variants Strain
The level of neutralizing antibody was detected by using the constructed pseudovirus covid-19 variant at baseline , 1 month , 6 months and 12 months after primary vaccination, within 15 days after booster immunization at 12…
- Trial name
- NCT05087277
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Hematologic Neoplasms, Influenza
Influenza Vaccination Strategy for Patients With Hematologic Malignancy
This randomized controlled trial evaluates and compares the immunogenicity of three different influenza vaccine formulations: high-dose trivalent (HD-IIV3), MF59-adjuvanted quadrivalent (aIIV4), and standard-dose trivalent…
- Conditions
- Hematologic Neoplasms, Influenza, Immunogenicity
- Trial name
- (HEM-FLU) (NCT07485855)
- Testing
- High-dose trivalent inactivated influenza vaccine (HD-IIV3), MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4), Standard-dose trivalent inactivated influenza vaccine (SD-IIV3)
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Asan Medical Center
Immunodeficiencies, Immune Dysregulations
COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Background: The immune system defends the body against disease and infection. Immune deficiencies are health conditions that decrease the strength of this response.
- Trial name
- PERSIST (NCT04852276)
- Where
- United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of the hAd5-S-Fusion+N-ETSD vaccine and select a dose for future studies.
- Trial name
- NCT04591717
- Testing
- hAd5-S-Fusion+N-ETSD vaccine
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Japanese Encephalitis, Vaccine Preventable Disease
Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province
This study is to evaluate the seroprevalence of neutralizing antibodies against Japanese encephalitis (JE) virus in children aged 6 years who were previously administered with 5 different immunization strategies by JE attenuated…
- Conditions
- Japanese Encephalitis, Vaccine Preventable Disease, Vaccine Reaction
- Trial name
- NCT04817917
- Testing
- Japanese Encephalitis Vaccine (Vero Cell), Inactivated;, No prospective interventions
- Where
- 3 sites in China
- Volunteers
- 712 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Sepsis
Effects of BCG on Immune Response
In the present study, we want to investigate whether BCG-vaccination enhances the innate immune response in humans in vivo during (single) human endotoxemia.
- Trial name
- NCT02085590
- Testing
- BCG vaccine, Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Infections, Meningococcal
Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs
The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of 3 doses of the meningococcal serogroup B vaccine when given, using either a 0-2-4 month or a 0-1-6 month schedule, to healthy adolescents…
- Trial name
- NCT00137917
- Testing
- Meningococcal serogroup B vaccine
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus
Human Papillomavirus (HPV) Vaccination Among Survivors of Childhood Cancer
This study will focus on the primary objectives: To estimate the prevalence of HPV vaccination among a large cohort of childhood cancer survivors and an acquaintance control group.
- Trial name
- NCT01117389
- Where
- United States
- Volunteers
- 587 people
- Sponsor
- St. Jude Children's Research Hospital
Smallpox
Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults
The purpose of this study is to gather information on the safety and the effectiveness of an investigational vaccine for the prevention of smallpox disease.
- Trial name
- NCT00079820
- Testing
- ACAM3000 MVA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis B, Immune Response
Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students
At present, children less than 15 y of age have been regarded as a key group for hepatitis B immunization in China. However, there is not yet special immunization strategy for population above 15 y of age.
- Conditions
- Hepatitis B, Immune Response, Seroprevalence
- Trial name
- NCT01861613
- Testing
- HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)
- Where
- China
- Volunteers
- 2,040 people, healthy volunteers welcome
- Sponsor
- Hui Zhuang
HIV Infections, Pregnancy
Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
PRIMARY: To evaluate the short-term safety of rgp120/HIV-1SF2 vaccine versus MF59 placebo administered to HIV-infected pregnant women.
- Conditions
- HIV Infections, Pregnancy, HIV Seronegativity
- Trial name
- NCT00001046
- Testing
- MF59, rgp120/HIV-1 SF-2
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
End Stage Renal Disease
Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
The purpose of this study is to compare the immune response to HEPLISAV™ booster injection with the immune response to Engerix-B® and Fendrix® booster vaccinations among patients with end stage renal disease (ESRD) on…
- Trial name
- NCT01195246
- Testing
- HEPLISAV, Engerix-B, Fendrix
- Where
- 19 sites in Germany
- Volunteers
- 155 people
- Sponsor
- Dynavax Technologies Corporation
Influenza
Influenza Vaccination of HIV Infected Pregnant Women: Safety and Immunogenicity
This randomized, placebo controlled trial will evaluate the safety and immunogenicity of Trivalent Influenza Vaccine (TIV) in HIV-infected pregnant women, dynamics of transplacental anti-influenza antibody transfer to their…
- Trial name
- MatfluHIVpos (NCT01306682)
- Testing
- Trivalent influenza vaccine, Normal saline
- Where
- South Africa
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- University of Witwatersrand, South Africa
Healthy Adult Volunteers
Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination
The investigators conduct a prospective analysis to compare homologous and heterologous adenovirus vector ChAdOx1-nCov-19 (Astra-Zeneca) or SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine inoculation.
- Trial name
- NCT05074368
- Testing
- ChAdOx1-nCov-19 (Astra-Zeneca), SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
- Where
- Taiwan
- Volunteers
- 499 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Hepatitis B, Chronic Hepatitis B
TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B
The goal of this clinical trial is to learn if HEPLISAV-B, a vaccine that is approved to prevent hepatitis B infection in people that are not already infected, is safe in people already chronically infected with hepatitis B.
- Trial name
- BOOST-9 (NCT04843852)
- Testing
- Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Maryland, Baltimore
Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections
A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)
This is a non-randomized, open label study to assess the reduction of Human Papillomavirus (HPV) infectivity and transmission in women positive for HPV16 and/or 18 in a cervical, oral and anal sample and vaccinated with…
- Conditions
- Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV, HPV-16/ 18
- Trial name
- RIFT-HPV (NCT05334706)
- Testing
- Nonavalent HPV vaccine (9vHPV/Gardasil-9™).
- Where
- Spain
- Volunteers
- 69 people
- Sponsor
- Miquel Angel Pavon Ribas
Poliomyelitis
Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT
This is a single site, phase 1 study of dmLT as a mucosal adjuvant to control fecal viral shedding when used in combination with intradermally administered fractional dose trivalent IPV (fIPV).
- Trial name
- NCT05327426
- Testing
- Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT), Intradermal fractional dose inactivated polio vaccine (fIPV), Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Obesity
Diet and COVID-19 Vaccination
Recently, obesity and excess visceral fat were shown to be major risk factors for the development of complications following Covid 19 infection.
- Trial name
- NCT05163743
- Testing
- Low Calorie Ketogenic Diet
- Where
- Italy
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Streptococcus Pyogenes Pharyngitis, Streptococcus Pharyngitis
Controlled Human Infection for Vaccination Against Streptococcus Pyogenes
Group A Streptococcus (GAS) infection is a major cause of death and disability globally with a disproportionately high burden in settings of disadvantage worldwide.
- Conditions
- Streptococcus Pyogenes Pharyngitis, Streptococcus Pharyngitis, Strep Throat, Streptococcus Pyogenes Infection
- Trial name
- CHIVAS (NCT03361163)
- Testing
- emm75 Streptococcus pyogenes (GAS M75, strain 611024)
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Andrew Steer
Influenza Vaccine, Cost-Effectiveness
Cost-effectiveness of the Influenza Vaccination
Background: In Bangladesh, seasonal influenza imposes considerable health and economic burden, particularly for those at high risk of severe disease.
- Conditions
- Influenza Vaccine, Cost-Effectiveness, Vaccination
- Trial name
- NCT05996549
- Testing
- Quadrivalent Influenza Vaccine
- Where
- Bangladesh
- Volunteers
- 2,567 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh